Syzygium cumini (L.) Skeels in the Treatment of Type 2 Diabetes
Results of a randomized, double-blind, double-dummy, controlled trial

Claudio Coimbra Teixeira, MD1, Letícia Schwerz Weinert1,
Daniel Cardoso Barbosa1, Cristina Ricken1, Jorge Freitas Esteves,
MD2 and Flávio Danni Fuchs, MD, PHD3

Address correspondence to Claudio C. Teixeira, MD, Departamento de
Farmacologia, ICBS, UFRGS, Rua Sarmento Leite, 550, CEP 90046-900, Porto
Alegre, RS, Brazil. E-mail: clauct@vortex.ufrgs.br

Tea, extracts, solutions, and other preparations from plants with a putative
antihyperglycemic effect have a worldwide utilization in the treatment of
diabetes (1). Among them, the tea prepared from leaves of jambolan [Syzygium
jambos (L.) Alston or Syzygium cumini (L.) Skeels] is largely used in our city (2)
and elsewhere (3). We demonstrated that the tea and extracts from different
parts of the plant had no effect in normal rats (4), rats with streptozotocin-
induced diabetes (5), and normal volunteers (6). An antihyperglycemic effect in
patients with diabetes, however, could not be ruled out, since its mechanism of
action could depend on specific abnormalities of diabetes in humans.

In this double-blind, double-dummy clinical trial, we randomized patients with
type 2 diabetes to receive a tea prepared from leaves of Syzygium cumini (two
grams per liter of water, taken as water substitute) plus placebo tablets, placebo
tea (prepared with dried leaves of Imperata brasiliensis Trinius) plus glyburide
tablets (5 mg twice a day), or placebo tea plus placebo tablets.

Fasting blood glucose levels decreased significantly in participants treated with
glyburide and did not change in those treated with the Syzygium cumini tea and
in the participants who received placebos from tea and glyburide (Table 1). BMI,
creatinine, γ-glutamyl transferase, alkaline phosphatase, SGOT, SGPT, 24-h
glicosuria, 24-h proteinuria, triglycerides, and total, LDL, and HDL cholesterol
did not vary significantly among the groups.

With this clinical trial, we have completed a cycle of experiments showing that
the tea and extracts prepared from leaves of Syzygium cumini are
pharmacologically inert. Patients and physicians should not rely on the putative
antihyperglycemic effect of this tea, and perhaps of other folk medicines, that
pretend to have such an effect. The investigation of plants with potential clinical
utility could start with a clinical trial testing the effect of folk preparations in
order to isolate the active principles of those products that show pharmacological activity in this model.

Table 1—
Fasting blood glucose levels in participants treated with
Syzygium cumini tea, glyburide, and placebos from tea and glyburide

Acknowledgments

This work was supported in part by grants from CNPq and FAPERGS, Brazil.

Footnotes

References


